Co-Diagnostics posted lower revenue in Q3 2025, primarily due to reduced grant income, but improved its net loss position through cost reductions and strategic pivots, including an AI unit launch and international expansion.

Co-Diagnostics reported a net loss of $7.7 million in Q2 2025 as revenue dropped to $0.16 million due to the lack of grant revenue. Operating expenses were reduced year-over-year, but the company continues to invest in its Co-Dx PCR platform.

Co-Diagnostics reported a significant decrease in revenue for Q1 2025, primarily due to the timing of grant revenue recognition, with total revenue at $0.1 million. Despite this, the company managed to reduce its operating expenses and net loss compared to the prior year, while maintaining a healthy cash position.

In Q4 2024, Co-Diagnostics generated $149,330 in revenue and posted an adjusted EPS of -$0.36. The company remained pre-commercial with limited product activity and continued development of its diagnostic platform.

Co-Diagnostics announced their Q3 2024 financial results, highlighting progress in their pipeline development and ongoing dialogue with the FDA regarding their 510(k) application.

Co-Diagnostics reported their financial results for the second quarter of 2024, highlighting the progress made, including the 510(k) application submission to the FDA for their new instrument and COVID-19 test kit for over-the-counter use.

Co-Diagnostics announced its first quarter financial results, highlighting progress with new manufacturing facilities and plans for FDA submissions and test development.

Co-Diagnostics reported progress towards strategic goals in Q4, including an Emergency Use Authorization submission to the FDA for their Co-Dx PCR Pro™ instrument, mobile app, and COVID-19 test. The company is also expanding production capacity and developing new tests.

Co-Diagnostics reported total revenue of approximately $2.5 million in the third quarter of 2023, including $2.3 million in grant revenue. The company is progressing in the development of other test indications beyond Covid-19 for the new platform: TB, multiplex respiratory, and HPV.

Co-Diagnostics reported its Q2 2023 financial results, noting a decline in COVID diagnostic kit sales but highlighted progress in expanding their PCR technology and advancements towards the FDA submission of the Co-Dx PCR Home platform.

Co-Diagnostics reported a decline in financial performance due to decreased COVID-related sales. However, they continued to advance their longer-term strategy, particularly with the Co-Dx PCR Home™ platform, and received grant awards.

Co-Diagnostics reported full year 2022 financial results, impacted by decreased demand for COVID-19 testing. The company is focusing on its Co-Dx PCR Home™ platform and its potential beyond COVID-19.

Co-Diagnostics reported lower third-quarter results due to decreased demand for their COVID-19 tests, but made substantial progress on their Co-Dx PCR Home™ platform, which is nearing its final stages and expects clinical trials to begin soon. The company's ability to generate positive cash flow supported further development and optimization efforts for their Co-Dx PCR Home platform.

Co-Diagnostics reported lower volumes for its Logix Smart™ COVID-19 Test in the second quarter, attributed to a reduction in mandated testing and government funding. The company is focusing on growing its international distributor network, expanding its infectious disease testing menu, and developing its at-home/point-of-care testing platform.

Co-Diagnostics reported a strong first quarter in 2022, achieving record revenue of $22.7 million and a diluted EPS of $0.34.

Co-Diagnostics reported record full year 2021 revenue of $97.9 million. The company highlighted its strengthened executive management team and advancements in its at-home/point-of-care diagnostics platform.

Co-Diagnostics reported strong Q3 2021 financial results, achieving record revenue of $30.1 million and a fully diluted EPS of $0.38. The company is optimistic about its upcoming point of care/at-home diagnostic platform and its potential impact on infectious disease diagnostics.

Co-Diagnostics reported a strong second quarter with revenue of $27.4 million, pre-tax income of $11.9 million, and diluted EPS of $0.33. The company is focused on delivering high-quality diagnostic testing kits and is positioned for future growth with investments in talent and R&D.

Co-Diagnostics reported a strong first quarter in 2021, with revenue reaching $20.0 million and diluted EPS of $0.26. The company is focused on developing rapid PCR diagnostic testing and expanding its product portfolio to meet global demand.

Co-Diagnostics reported record fourth-quarter results, driven by demand for its Logix Smart COVID-19 Test. Revenue reached $27.1 million, and pre-tax income was $15.8 million.

Co-Diagnostics announced financial results for the third quarter ended September 30, 2020, reporting widespread uptake of their COVID-19 test domestically and abroad. The company also received CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests.

Co-Diagnostics reported strong Q1 2020 results driven by robust sales of COVID-19 tests and achieved net profitability through the middle of the second quarter of 2020.